Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low affinity heparin is an antithrombotic agent

E Gray1, S Cesmeli, J C Lormeau

  • 1National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK.

Thrombosis and Haemostasis
|February 1, 1994
PubMed
Summary

Low affinity heparin (LAH) shows potent antithrombotic activity in preventing venous thrombosis. While less effective than unfractionated heparin (UFH), LAH demonstrates a potentially lower bleeding risk, making it a promising alternative.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours.

ESMO open·2025
Same author

Corrigendum to "Mangrove preservation could have significantly reduced damages from Hurricane Otis on the coast of Guerrero, Mexico" [Sci. Total Environ. (2024), 177822].

The Science of the total environment·2025
Same author

Mangrove preservation could have significantly reduced damages from Hurricane Otis on the coast of Guerrero, Mexico.

The Science of the total environment·2024
Same author

Stop and Go: Barriers and Facilitators to Care Home Research.

The Journal of frailty & aging·2023
Same author

An update on oral cavity cancer: epidemiological trends, prevention strategies and novel approaches in diagnosis and prognosis.

Community dental health·2022
Same author

Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study.

ESMO open·2021

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Hemorrhage Studies

Background:

  • Heparins are crucial anticoagulants, but unfractionated heparin (UFH) carries a significant bleeding risk.
  • Low affinity heparin (LAH) presents a potential alternative with a modified risk-benefit profile.

Purpose of the Study:

  • To evaluate the antithrombotic efficacy of LAH in a rabbit model.
  • To assess the hemorrhagic side effects associated with LAH administration.
  • To compare LAH's activity and safety profile with UFH and dermatan sulfate.

Main Methods:

  • Antithrombotic activity assessed using a rabbit stasis thrombosis model with activated human serum.
  • Hemorrhagic side effects evaluated via a rabbit ear template bleeding time model.
  • Pharmacokinetic analysis using heparin cofactor II and anti-factor Xa assays.

Related Experiment Videos

  • Thrombin generation inhibition measured in post-injection plasma samples.

    • Main Results:

    • LAH significantly reduced thrombus formation in a dose-dependent manner at 10' and 20' stasis.
    • Complete prevention of thrombosis was observed at 500 µg/kg (10' stasis) and 1000 µg/kg (20' stasis).
    • Peak plasma levels of LAH were measured, correlating with an 80% reduction in thrombin generation.
    • LAH showed a mean bleeding time ratio of 1.25 at 2.5 mg/kg, indicating a lower hemorrhagic risk compared to UFH.

    Conclusions:

    • Low affinity heparin exhibits significant antithrombotic effects, particularly in venous thrombosis models.
    • LAH demonstrates a more favorable safety profile regarding bleeding risk compared to unfractionated heparin.
    • LAH is more potent than dermatan sulfate in preventing venous thrombosis but less potent than UFH on a weight basis.